The following link is to the Cancer Therapy Advisor website featuring the following video
Meletios Dimopoulos, MD, discusses his findings at the ASCO 2018 meeting in Chicago.
Download PDF WhiMSICAL Study
Waldenström’s Macroglobulinemia Study Involving CART-WHEEL
A world-first, ethically-approved, comprehensive global database
of patient-derived data about your WM experience
Join WhiMSICAL to “pay it forward” and help WM patients around the… Continue reading
If you were not able to attend the workshop on 4 October 2017, “What’s New in the Treatment of Waldenstrom’s Macroglobulinemia (WM),” it is available online via webcast here (link is external) or on telephone replay… Continue reading
BGB-3111 is a potent and highly selective small molecule BTK inhibitor (Bruton’s Tyrosine Kinase), which we are developing as a monotherapy and in combination with other therapies for the treatment of a variety of lymphomas—the most common form of blood… Continue reading
Judith Trotman, MD, clinical associate professor, medicine, Concord Clinical School, The University of Sydney, discusses results of a trial investigating BGB-3111 in patients with Waldenstrom’s macroglobulinemia (WM).
BGB-3111 is a very specific BTK inhibitor that has a very high, very… Continue reading